INT108342

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 18
Total Number 18
Disease Relevance 9.48
Pain Relevance 4.46

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (EPHB2)
Anatomy Link Frequency
endothelial cells 1
DRt 1
eosinophils 1
EPHB2 (Homo sapiens)
Pain Link Frequency Relevance Heat
opioid receptor 10 99.96 Very High Very High Very High
agonist 131 98.72 Very High Very High Very High
aspirin 20 98.16 Very High Very High Very High
Enkephalin 3 98.04 Very High Very High Very High
mu opioid receptor 3 97.80 Very High Very High Very High
antagonist 8 96.60 Very High Very High Very High
Morphine 83 96.12 Very High Very High Very High
Delta opioid receptors 5 95.96 Very High Very High Very High
ischemia 8 92.80 High High
gABA 1 92.44 High High
Disease Link Frequency Relevance Heat
Acquired Immune Deficiency Syndrome Or Hiv Infection 33 100.00 Very High Very High Very High
Stress 23 98.40 Very High Very High Very High
Eosinophilia 16 98.40 Very High Very High Very High
Apoptosis 152 97.80 Very High Very High Very High
Ovarian Cancer 4 97.56 Very High Very High Very High
Cancer 231 95.88 Very High Very High Very High
Colon Cancer 45 94.16 High High
Primary Sclerosing Cholangitis 2 93.08 High High
Cv Unclassified Under Development 6 92.80 High High
Hepatocellular Cancer 4 92.40 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Cell growth can be inhibited by both a sustained increase and decrease in Erk1/2 activity [37].
Negative_regulation (decrease) of Erk1
1) Confidence 0.57 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2918577 Disease Relevance 0 Pain Relevance 0
inhibiting ERK1/2 [50].
Negative_regulation (inhibiting) of ERK1
2) Confidence 0.57 Published 2008 Journal PPAR Research Section Body Doc Link PMC2408682 Disease Relevance 1.32 Pain Relevance 0.05
In BECs, a specific inhibitor of ERK1/2 abrogates phosphorylation of ELK-1 and protein expression of TLR4 but not TLR9 [105].


Negative_regulation (inhibitor) of ERK
3) Confidence 0.42 Published 2010 Journal Fibrogenesis Tissue Repair Section Body Doc Link PMC2984459 Disease Relevance 1.78 Pain Relevance 0.46
function and cell growth by inhibiting ERK1/2 [50].
Negative_regulation (inhibiting) of ERK1
4) Confidence 0.42 Published 2008 Journal PPAR Research Section Body Doc Link PMC2408682 Disease Relevance 0.89 Pain Relevance 0.39
In BECs, a specific inhibitor of ERK1/2 abrogates phosphorylation of ELK-1 and protein expression of TLR4 but not TLR9 [105].


Negative_regulation (inhibitor) of ERK1
5) Confidence 0.42 Published 2010 Journal Fibrogenesis Tissue Repair Section Body Doc Link PMC2984459 Disease Relevance 1.78 Pain Relevance 0.46
inhibitors (Rp-cAMPs, KT5720 or others), ERK1/2 inhibitors, and protein
Negative_regulation (inhibitors) of ERK1
6) Confidence 0.42 Published 2008 Journal Neural Plasticity Section Body Doc Link PMC2435227 Disease Relevance 0.27 Pain Relevance 0.27
In fact, this may be true as a p38 MAP kinase inhibitor, SB239063 has been shown to almost completely abolish lung eosinophilia in ovalbumin-sensitized and challenged mice.111 In contrast to p38 MAP kinase, inhibition of ERK 1/2 activity seems not to alter the rate of spontaneous apoptosis in eosinophils.92
Negative_regulation (inhibition) of ERK 1 in eosinophils associated with apoptosis and eosinophilia
7) Confidence 0.42 Published 2010 Journal Allergy, Asthma & Immunology Research Section Body Doc Link PMC2846745 Disease Relevance 0.76 Pain Relevance 0
Blocking the function of CXCR2 by either neutralizing antibodies or inhibiting downstream signalling using specific inhibitors of ERK1/2 and PI3 kinase impaired IL-8-induced stress fiber assembly, chemotaxis, and endothelial tube formation in endothelial cells [39,54].
Negative_regulation (inhibitors) of ERK1 in endothelial cells associated with stress
8) Confidence 0.42 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2895614 Disease Relevance 0.29 Pain Relevance 0.11
A 1 h exposure to 3 mM VPA significantly decreased the degree of Erk1/2 phosphorylation.
Negative_regulation (degree) of Erk1
9) Confidence 0.41 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2918577 Disease Relevance 0 Pain Relevance 0
Furthermore, the effects of VPA on the degree of Erk1/2 phosphorylation and HDAC inhibition were not related to the degree of Erk1/2 phosphorylation and acetylation in the absence of the drug.
Negative_regulation (inhibition) of Erk1
10) Confidence 0.41 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2918577 Disease Relevance 0 Pain Relevance 0
Furthermore, the effects of VPA on the degree of Erk1/2 phosphorylation and HDAC inhibition were not related to the degree of Erk1/2 phosphorylation and acetylation in the absence of the drug.
Negative_regulation (degree) of Erk1
11) Confidence 0.41 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2918577 Disease Relevance 0 Pain Relevance 0
However, VPA caused equally strong inhibition of Erk1/2 phosphorylation in control- and caRas-transfected cells (Figure 5b, lanes 3 and 4).
Negative_regulation (inhibition) of Erk1
12) Confidence 0.41 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2918577 Disease Relevance 0 Pain Relevance 0
Similarly, pretreatment with sulindac sulfide blocks the ability of EGF to induce ERK1/2 and Bad phosphorylation, but also down-regulates total Bad but not ERK1/2 protein levels.
Negative_regulation (down-regulates) of ERK
13) Confidence 0.41 Published 2003 Journal Cancer Res. Section Abstract Doc Link 12566304 Disease Relevance 1.16 Pain Relevance 0.14
LMB at a low concentration is a potent and specific inhibitor of many proteins including the HIV-1 Rev protein, MAPK/ERK, and the nuclear export protein CRM1 [50], [51].
Negative_regulation (inhibitor) of ERK associated with acquired immune deficiency syndrome or hiv infection
14) Confidence 0.41 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2605563 Disease Relevance 0.10 Pain Relevance 0.46
In particular, the analogue displaying two nitro-oxy functions fully mimicked the known inhibitory properties of celecoxib, including inhibition of COX-2, as well as of ERK/MAPK and beta-catenin signalling pathways.
Negative_regulation (inhibition) of ERK
15) Confidence 0.41 Published 2009 Journal Chem. Biol. Interact. Section Abstract Doc Link 19682443 Disease Relevance 0.53 Pain Relevance 0.09
We conclude that ERK/MAP kinase activity prevents opioid receptor desensitization and sequestration by blocking arrestin 2 interaction with activated DORs.
Negative_regulation (prevents) of ERK associated with delta opioid receptors and opioid receptor
16) Confidence 0.41 Published 2004 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 14742744 Disease Relevance 0 Pain Relevance 0.78
The ERK1/2 signaling pathways were blocked pharmacologically by addition of the MEK inhibitor, PD98059.
Negative_regulation (blocked) of ERK1
17) Confidence 0.41 Published 2010 Journal Parasit Vectors Section Body Doc Link PMC2993695 Disease Relevance 0 Pain Relevance 0.04
To increase the opioidergic inhibition of the DRt, we locally injected selective agonists of delta- and mu-opioid receptors or a viral vector containing the human preproenkephalin transgene.
Negative_regulation (inhibition) of DRt in DRt associated with mu opioid receptor and agonist
18) Confidence 0.23 Published 2008 Journal Mol. Cell. Neurosci. Section Abstract Doc Link 18725300 Disease Relevance 0.59 Pain Relevance 1.21

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox